Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

fibonacci1170 Aug. 6 at 7:26 PM

$CLNN only 8 more weeks until NfL data. If accelerated approval is granted, FDA commissioner Makary will be talking about this drug on every news channel, every meeting, every newsletter, every podcast. "CNM-AU8 the new drug for ALS" will become the poster boy of this new FDA. So hang tight. Because we are close.

3 · Reply

josh77 Aug. 5 at 7:23 PM

$CLNN

0 · Reply

NetworkNewsWire Aug. 5 at 4:04 PM

BioMedNewsBreaks — $CLNN to Present at Canaccord 45th Annual Growth Conference https://ibn.fm/NAgsD

0 · Reply

fibonacci1170 Aug. 5 at 2:01 PM

$CLNN fda is expected to see the NfL data from ~400 patients by mid-october. If good, accelerated approval is in the bag. Mcap is $35MIL. AMLX had a $4BIL mcap before it's drug was withdrawn from the market. We have 100x upside, at least. Fingers crossed for a stellar NfL data 🤞

1 · Reply

Bayon Aug. 4 at 10:17 PM

$CLNN calm

0 · Reply

Bobfree Aug. 2 at 4:56 PM

$CLNN A nice article from a physician turned patient on why accelerated ALS treatment approval is absolutely warranted and needed NOW. https://www.newsweek.com/doctors-plea-nation-asleep-brain-disease-opinion-2106026 Fyi, yes this is advocating primairly for NurOwn, and no, I dont care. Both should be immediately approved in my opinion.

0 · Reply

neuroinvestor3 Aug. 1 at 8:20 PM

$CLNN any speculation on why 362K CLNN shares were traded today?

1 · Reply

Scoops1212 Aug. 1 at 1:05 PM

$CLNN

0 · Reply

NetworkNewsWire Jul. 31 at 6:25 PM

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease $CLNN https://ibn.fm/O1GaM #biomedstocks #Parkinson’s

0 · Reply

fibonacci1170 Jul. 29 at 10:09 AM

$CLNN Hi, what are your thoughts on DRR=0.98. It means CNM-Au8 was no more effective than placebo in slowing disease progression. I am quite surprised the FDA even wants to see NfL data. Biomarkers don't mean much if DRR~1. If NfL data is good, will FDA stick to its semi-promise of granting accelerated approval? Or will it reject because DRR=0.98? I personally don't see how and why a DRR=0.98 drug should get approved for any disease. What are your thoughts?

2 · Reply

Clene to Present at the Canaccord 45th Annual Growth Conference

Jun 30, 2025, 8:00 AM EDT - 5 weeks ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 2 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 3 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 14, 2025, 8:30 AM EDT - 4 months ago

Clene to Present at the Emerging Growth Conference

Apr 1, 2025, 8:30 AM EDT - 4 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 5 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 5 months ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 5 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 5 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 8 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 11 months ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 11 months ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 1 year ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 1 year ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Pricing of $40 Million Public Offering

Jun 15, 2023, 4:38 PM EDT - 2 years ago

Clene Announces Launch of Proposed Public Offering

Jun 15, 2023, 4:29 PM EDT - 2 years ago

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Jun 15, 2023, 7:00 AM EDT - 2 years ago

Clene to Participate in the Maxim Group Virtual Healthcare Conference

May 12, 2023, 4:00 PM EDT - 2 years ago

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

Apr 25, 2023, 4:05 PM EDT - 2 years ago

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

fibonacci1170 Aug. 6 at 7:26 PM

3 · Reply

josh77 Aug. 5 at 7:23 PM

$CLNN

0 · Reply

NetworkNewsWire Aug. 5 at 4:04 PM

BioMedNewsBreaks — $CLNN to Present at Canaccord 45th Annual Growth Conference https://ibn.fm/NAgsD

0 · Reply

fibonacci1170 Aug. 5 at 2:01 PM

1 · Reply

Bayon Aug. 4 at 10:17 PM

$CLNN calm

0 · Reply

Bobfree Aug. 2 at 4:56 PM

0 · Reply

neuroinvestor3 Aug. 1 at 8:20 PM

$CLNN any speculation on why 362K CLNN shares were traded today?

1 · Reply

Scoops1212 Aug. 1 at 1:05 PM

$CLNN

0 · Reply

NetworkNewsWire Jul. 31 at 6:25 PM

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease $CLNN https://ibn.fm/O1GaM #biomedstocks #Parkinson’s

0 · Reply

fibonacci1170 Jul. 29 at 10:09 AM

2 · Reply

Impatient_Investor Jul. 29 at 6:41 AM

$CLNN

1 · Reply

Scoops1212 Jul. 28 at 11:34 PM

$CLNN

0 · Reply

NetworkNewsWire Jul. 28 at 7:04 PM

$CLNN Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate https://ibn.fm/jaGBt

0 · Reply

neuroinvestor3 Jul. 28 at 2:01 PM

$CLNN anyone else smelling a pending dilution event? Higher volume last week with no news... FDA needs to give Clene accelerated approval for ALS treatment soon. Product works. It's not a home run, but it will delay progression in almost all neurodegenerative diseases. Delayed symptoms, severity, and death is a winner so I'm buying more once they get done with raising survival cash.

2 · Reply

josh77 Jul. 28 at 1:46 PM

$CLNN

0 · Reply

NetworkNewsWire Jul. 28 at 1:03 PM

BioMedNewsBreaks — $CLNN Builds Momentum to Bring New Hope to Neuro Patients https://ibn.fm/t3Lli

0 · Reply

josh77 Jul. 27 at 9:46 PM

$CLNN https://www.youtube.com/watch?v=j0C4_WxsdYg

0 · Reply

josh77 Jul. 27 at 9:45 PM

$CLNN https://www.youtube.com/watch?v=leWiWpHOqTM&t=1640s

0 · Reply

Impatient_Investor Jul. 26 at 4:22 PM

$CLNN

1 · Reply

Bobfree Jul. 25 at 3:38 PM

$CLNN limit order is filling less than 100 shares at a time, crazy low volume

0 · Reply

Scoops1212 Jul. 25 at 2:19 PM

$CLNN

0 · Reply

Bayon Jul. 22 at 10:08 PM

$CLNN wake up sleeping beauty.

0 · Reply

Market Cap	30.51M
Revenue (ttm)	340,000.00
Net Income (ttm)	-39.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,588.24%
Debt to Equity Ratio	-0.39

Volume	14,800
Avg Vol	99,400
Day's Range	N/A - N/A
Shares Out	8.27M
Stochastic %K	65%
Beta	0.55
Analysts	Strong Sell
Price Target	$35.71